Multiomic Health

AI-ENABLED PRECISION MEDICINE FOR METABOLIC-SYNDROME-RELATED CONDITIONS

ABOUT.

Multiomic is a next-generation precision medicine business, applying computational systems biology to develop and commercialize data assets for metabolic syndrome — the world’s largest healthcare burden. With our unique combination of data science and biology expertise, we are enabling data-driven development of therapeutics and are bringing understanding into complex biological systems.

Metabolic syndrome, a cluster of closely-related diseases (atherosclerotic cardiovascular disease, type 2 diabetes, chronic kidney disease, non-alcoholic fatty liver) with many common risk factors, is costing the healthcare system $2 trillion (forecast >$5.5 trillion by 2040). It is a 1.6x larger market than oncology, yet attracts only 40% of the VC dollars.

CARDIOVASCULAR DISEASE

The most common cause of death worldwide

TYPE 2
DIABETES

Major impact on patients’ lifestyle and CVD risk

CHRONIC KIDNEY DISEASE

One of the main risk factors for development of cardiometabolic diseases

NON-ALCOHOLIC FATTY LIVER

Metabolic disease without an efficient long-term treatment

OUR FOCUS.

A major unmet need is the lack of high-fidelity tools to focus the right treatments on the right patients. In oncology, treatments are personalized based on genetic and protein biomarkers whereas metabolic syndrome patients are being prescribed drugs based on their blood pressure, fasting glucose and cholesterol levels. As metabolic syndrome is a complex multifactorial condition, it requires systems medicine models and composite biomarkers that were hitherto infeasible. ML-enabled data science and rapidly-falling omics costs have changed the game and we are aiming at becoming the leader in this space

STATISTICS.

METABOLIC SYNDROME PANDEMIC

#
cause of death globally - 45% of all deaths result from metabolic syndrome conditions
bn
adults are affected by metabolic syndrome worldwide
m
CHILDREN AND ADOLESCENTS EVENTUALLY TO DEVELOP METABOLIC SYNDROME
$tn
global healthcare cost burden of metabolic syndrome conditions

please view sidebar for data sources.

WHAT WE DO

MULTI Omic ANalysis.

GENOMICS

Genetic variants that influence the baseline risk for diseases

EPIGENOMICS

Regulation that defines the activity or inactivity of disease or protective gene variants

TRANSCRIPTOMICS

Gene activity and their unfolding into biological action in the body

PROTEOMICS

Proteins that drive protection from, response to and the development of the disease

METABOLOMICS

Intermediary metabolites that enlighten metabolic processes in health and disease

PHENOMICS

Physiological and morphological output of biology

UNDERSTANDING CHRONIC DISEASE BIOLOGY

EXPERTS IN THEIR FIELDS

OPERATING TEAM.

Robert Thong

CO-FOUNDER, Chairman & CEO

30+ years in biopharma and healthcare, with a strong focus on R&D strategy/management, B2B partnerships and enterprise value creation. Has engaged with 100+ organizations in biopharma, medical technology and healthcare. Published authority on biopharma R&D alliances and biotech business models

Slaven Stekovic

PRESIDENT & COO

Forbes 30under30. Founded a cellular ageing biotech startup (The Longevity Labs GmbH, whose award-winning nutraceutical is now marketed in >14 countries incl. US), exited after 3 years. Operational leadership roles at two other data-intensive startups in cancer genomics and AI-enabled robotics respectively

Cristina Balagué

HEAD OF DISEASE BIOLOGY

20 years of drug discovery program leadership. Experienced across multiple disease areas, from target validation to preclinical development and regulatory. Chaired new therapeutic program generation activities at Almirall, a leading European mid-sized pharma

Celia Antonio Schell

HEAD OF CLINICAL OPERATIONS

14 years experience in clinical research at Novartis and ICON (global CRO) including 10 years of managing international clinical studies. Most recent prior role was managing a global Phase III clinical study of >7,000 patients across 43 countries for a cardiovascular drug

Ariella Cohain

HEAD OF COMPUTATIONAL BIOLOGY

Deep technical capabilities, strong academic network and author of multiple scientific papers on system biology modeling of cardiometabolic diseases. Most recent prior role was leading a data science team at a Boston-based biotech that was acquired for >$2 billion

Andrew Parton

Lead DATA SCIENTIST

Accomplished systems biology modeler. Most recently at the European Bioinformatics Institute. Prior to this, conducted academic research and published on atherosclerosis modeling

Esra Berkol

CHIEF OF STAFF & MARKETING MANAGER

Broad experience base in collaborative contexts. Product manager in a B2B financial data & solutions provider. Project manager in an energy & fintech business. Has founded and exited her own business

Henrietta Bull

MARKETING & BUSINESS ANALYST

Analyst working at the cross-section of business and bioscience, with an MSc in Bioscience Entrepreneurship and a BSc in Biomedical Sciences. Prior experience includes working in bioscience SMEs across marketing and business development functions, as well as pharmaceutical R&D

Becky Cripps

BUSINESS & SCIENCE ANALYST

Analyst working across the bioscience and business interface with Master’s degree in Bioscience Entrepreneurship and Bachelor’s degree in biochemistry. Previous experience working in a range of healthcare-centred roles, spanning project support in primary care training to life sciences public relations

Contact.

Want to be a part of our team?

Got a partnership in mind?

Get in touch with us and know more about how we are changing the face of healthcare.

THE COMPANY

Multiomic Health Limited is a registered UK company 

Company #13246608

ADDRESS

Epworth House 

25 City Road, Shoreditch, London, EC1Y 1AA

Connect
EMAIL US

info@multiomic.health